/
Infectious Disease
Hepatitis
120
Pipeline Programs↗
144
Active Trials↗
129
Companies Involved↗
Hepatitis is a highly competitive landscape with 120 programs across 129 companies. The most active players are Innovent Biologics (Suzhou) Co. Ltd., Rivus Pharmaceuticals, Inc., Corcept Therapeutics. 27 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical48
Phase 19
Phase 236
Phase 327
Approved
No programs
Analysis
Modality Breakdown
86%
Small molecule
85 of 99 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 99 classified programs, each share of the total. Modality classified for 97% of 120 pipeline programs.
Analysis
Trial Status
1,334
clinical trials
Completed824 · 62%
Unknown status192 · 14%
Terminated124 · 9%
Recruiting68 · 5%
Withdrawn44 · 3%
Active, not recruiting41 · 3%
Other41 · 3%
Clinical Trials
Trial Activity
1334 trials
ASC22 Combined With Peg-IFNa in Achieving Functional Cure in Patients With Chronic Hepatitis B Virus Infection
Recruiting·TThe Second Affiliated Hospital of Chongqing Medical University·Approved·NCT07573943·120 enrolled
A Pilot Study of the Combination of VIR-2218 and Peginterferon Alfa-2a for Chronic Hepatitis B
Recruiting·National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 2·NCT06092333·50 enrolled
Page 1 of 89
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)